## **AMENDMENTS TO THE CLAIMS**

- 1. 10. (Canceled)
- 11. (Currently Amended) A process for preventing or treating hypertension or high blood pressure comprising: administering an effective dose of a composition comprising (a) ferulic acid or an ester thereof, or a pharmaceutically acceptable salt thereof, and (b) a component selected from caffeic acid, chlorogenic acid, caffeic acid and chlorogenic acid, and pharmaceutically acceptable salts thereof, to a subject in need thereof, wherein systolic blood pressure, diastolic blood pressure, or both is reduced.
  - 12. (Original) The process of Claim 11, wherein systolic blood pressure is reduced.
  - 13. (Original) The process of Claim 11, wherein diastolic blood pressure is reduced.
  - 14. 19. (Canceled)
- 20. (New) The process of Claim 11, wherein systolic and diastolic blood pressure is reduced.
- 21. (New) The process of Claim 11, wherein (b) is caffeic acid or a pharmaceutically acceptable salt thereof.
- 22. (New) The process of Claim 11, wherein (b) is chlorogenic acid or a pharmaceutically acceptable salt thereof.
- 23. (New) The process of Claim 11, wherein (b) is caffeic acid and chlorogenic acid or a pharmaceutically acceptable salt thereof.
- 24. (New) The process of Claim 11, wherein (a) is ferulic acid or a pharmaceutically acceptable salt thereof.
- 25. (New) The process of Claim 11, wherein (a) is an ester of ferulic acid or a pharmaceutically acceptable salt thereof.
- 26. (New) The process of Claim 11, wherein the effective dose of (a) ranges from 0.001 to 10 g per day per.

- 27. (New) The process of Claim 11, wherein the effective dose of (a) ranges from 0.005 to 5 g per day per.
- 28. (New) The process of Claim 11, wherein the effective dose of (a) ranges from 0.01 to 0.5 g per day per.
- 29. (New) The process of Claim 11, wherein the effective dose of (b) ranges from 0.001 to 10 g per day per.
- 30. (New) The process of Claim 11, wherein the effective dose of (b) ranges from 0.005 to 5 g per day per.
- 31. (New) The process of Claim 11, wherein the effective dose of (b) ranges from 0.01 to 0.5 g per day per.
- 32. (New) The process of Claim 11, wherein the weight ratio of (a) to (b) ranges from 0.01 to 50.
- 33. (New) The process of Claim 11, wherein the weight ratio of (a) to (b) ranges from 0.01 to 5.
- 34. (New) The process of Claim 11, wherein the total amount of (a) and (b) administered per day ranges from 0.001 to 20 g.
- 35. (New) The process of Claim 11, wherein the total amount of (a) and (b) administered per day ranges from 0.005 to 10 g.
  - 36. (New) The process of Claim 11, wherein said administering is orally.
  - 37. (New) The process of Claim 11, wherein said administrating is parenterally.
- 38. (New) The process of Claim 11, wherein said process further comprises adding said composition to a food or beverage prior to said administering.

## SUPPORT FOR THE AMENDMENTS

Claims 7, 9, and 10 were previously canceled.

Claims 1-6, 8, and 14-19 are canceled herein.

Claim 11 has been amended.

Claims 20-38 have been added.

Support for the amendment of Claim 11 is provided by original Claims 11-13. New Claims 20-38 are supported by pages 6-12 of the specification and further supported by the Examples.

No new matter has been added by the present amendments.